Amyris Strikes Agreements For Financing

Amyris shares were nearly 7% higher Thursday after the industrial bioscience company said it has reached agreements for $50 million in equity financing as part of the second tranche of its previously announced financing.

The financing is being led by a $25-million investment from Koninklijke DSM and the remaining from Vivo Capital, a healthcare investment firm. Following the close of this tranche, Vivo Capital will be granted an Amyris board seat and DSM gains an additional board seat.

By Brianna Stevens